Target Information

Target General Infomation
Target ID
T06475
Former ID
TTDR00575
Target Name
Nucleolin
Gene Name
NCL
Synonyms
Nucleolin; Protein C23; NCL
Target Type
Clinical Trial
Disease Cancer [ICD9: 140-229; ICD10: C00-C96]
Leukemia [ICD9: 208.9; ICD10: C90-C95]
Function
Nucleolin is the major nucleolar protein of growing eukaryotic cells. It is found associated with intranucleolar chromatin and pre-ribosomal particles. It induces chromatin decondensation by binding to histone H1. It is thought to play a role in pre-rRNA transcription and ribosome assembly. May play a role in the process of transcriptional elongation. Binds RNA oligonucleotides with 5'-UUAGGG-3' repeats more tightly than the telomeric single-stranded DNA5'-TTAGGG-3' repeats.
BioChemical Class
RNA recognition motif
UniProt ID
P19338
Sequence
MVKLAKAGKNQGDPKKMAPPPKEVEEDSEDEEMSEDEEDDSSGEEVVIPQKKGKKAAATS
AKKVVVSPTKKVAVATPAKKAAVTPGKKAAATPAKKTVTPAKAVTTPGKKGATPGKALVA
TPGKKGAAIPAKGAKNGKNAKKEDSDEEEDDDSEEDEEDDEDEDEDEDEIEPAAMKAAAA
APASEDEDDEDDEDDEDDDDDEEDDSEEEAMETTPAKGKKAAKVVPVKAKNVAEDEDEEE
DDEDEDDDDDEDDEDDDDEDDEEEEEEEEEEPVKEAPGKRKKEMAKQKAAPEAKKQKVEG
TEPTTAFNLFVGNLNFNKSAPELKTGISDVFAKNDLAVVDVRIGMTRKFGYVDFESAEDL
EKALELTGLKVFGNEIKLEKPKGKDSKKERDARTLLAKNLPYKVTQDELKEVFEDAAEIR
LVSKDGKSKGIAYIEFKTEADAEKTFEEKQGTEIDGRSISLYYTGEKGQNQDYRGGKNST
WSGESKTLVLSNLSYSATEETLQEVFEKATFIKVPQNQNGKSKGYAFIEFASFEDAKEAL
NSCNKREIEGRAIRLELQGPRGSPNARSQPSKTLFVKGLSEDTTEETLKESFDGSVRARI
VTDRETGSSKGFGFVDFNSEEDAKAAKEAMEDGEIDGNKVTLDWAKPKGEGGFGGRGGGR
GGFGGRGGGRGGRGGFGGRGRGGFGGRGGFRGGRGGGGDHKPQGKKTKFE
Structure
2FC8; 2FC9; 2KRR
Drugs and Mode of Action
Drug(s) ACT-GRO-777 Drug Info Phase 2 Cancer [522416]
Itarnafloxin Drug Info Phase 2 Leukemia [544179]
IPP-204106 Drug Info Phase 1/2 Cancer [524099]
Modulator IPP-204106 Drug Info
Inhibitor Itarnafloxin Drug Info [544179]
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
Pathways
NetPath Pathway TCR Signaling Pathway
IL2 Signaling Pathway
Pathway Interaction Database Aurora B signaling
Validated targets of C-MYC transcriptional activation
Regulation of Telomerase
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
WikiPathways Pathogenic Escherichia coli infection
miR-targeted genes in squamous cell - TarBase
miR-targeted genes in muscle cell - TarBase
miR-targeted genes in lymphocytes - TarBase
miR-targeted genes in epithelium - TarBase
References
Ref 522416ClinicalTrials.gov (NCT00740441) A Phase II Study of AS1411 in Renal Cell Carcinoma. U.S. National Institutes of Health.
Ref 524099ClinicalTrials.gov (NCT01711398) Dose-finding Adaptive Phase I/IIa Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of IPP-204106N on Advanced Solid Tumors. U.S. National Institutes of Health.
Ref 544179Targeting G-quadruplexes in gene promoters: a novel anticancer strategy?. Nat Rev Drug Discov. 2011 April; 10(4): 261-275.
Ref 544179Targeting G-quadruplexes in gene promoters: a novel anticancer strategy?. Nat Rev Drug Discov. 2011 April; 10(4): 261-275.
Ref 544429Nucleic Acid Aptamers as Potential Therapeutic and Diagnostic Agents for Lymphoma. J Cancer Ther. 2013 June 1; 4(4): 872-890.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.